Relmada Therapeutics gets Nasdaq transfer to Capital Market and 180-day bid-price extension

RELMADA THERAPEUTICS, INC.

Nasdaq approved transfer to Capital Market effective July 24, 2025.
Company granted until January 19, 2026 to regain $1 minimum bid price compliance.
Must achieve closing bid price of $1.00 for 10 consecutive business days to regain compliance.
Company intends to monitor bid price and take reasonable measures to maintain listing.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.